Can I Take Folate with Prometrium?

Prometrium and folate: what each one actually is

Prometrium is the brand name for oral micronized progesterone, a progestogen structurally identical to the progesterone made by the ovaries. Micronization reduces particle size so the hormone is absorbed reliably when swallowed. The FDA-approved label lists two indications: prevention of endometrial hyperplasia in postmenopausal women taking estrogen, and treatment of secondary amenorrhea (according to Prometrium's FDA-approved prescribing information). Use for luteal support in fertility treatment or for catamenial epilepsy is off-label; it is common in reproductive endocrinology practice but is not the FDA-approved use.

Folate is the general name for vitamin B9, needed for DNA synthesis and one-carbon metabolism. It comes from food (leafy greens, legumes, fortified grains) and from supplements in two main forms: synthetic folic acid, and 5-methyltetrahydrofolate (5-MTHF, often called methylfolate), the form that circulates in blood after conversion. The National Institutes of Health Office of Dietary Supplements sets the adult RDA at 400 mcg dietary folate equivalents daily, higher in pregnancy, with a tolerable upper intake level of 1,000 mcg per day for folic acid from supplements and fortified food (NIH ODS folate fact sheet). That upper limit applies to folic acid specifically, not to food folate or to methylfolate.

Is there a known interaction between folate and Prometrium?

No pharmacokinetic or pharmacodynamic interaction between folate and Prometrium has been documented in major interaction references or in the FDA label. Prometrium is metabolized in the liver, largely through CYP3A4 and related pathways, into inactive metabolites that are cleared renally, according to its FDA label. Folate and methylfolate are absorbed through a dedicated intestinal transporter and, at ordinary supplemental doses, do not meaningfully induce or inhibit the liver enzymes that clear progesterone. Because the two compounds do not compete for the same enzymes, transporters, or hormone receptors, there is no established mechanism by which one would change blood levels or effectiveness of the other. This is consistent with the absence of an interaction flag for this pairing in standard drug-interaction checkers, though absence of a flag reflects absence of reported signal rather than a dedicated study designed to rule an interaction out.

Nothing in the available evidence suggests folate changes the endometrial protective effect of progesterone, and nothing suggests progesterone measurably worsens or improves folate status in a typical supplemented adult. If a reader wants dosing or spacing instructions specific to their own labs, medications, or pregnancy status, that decision belongs with the prescriber or pharmacist who can see the full medication list, not a general reference page.

MTHFR variants: the part that actually changes the folate decision

The enzyme MTHFR converts folic acid into the active circulating form, 5-MTHF. Common genetic variants (often labeled C677T or A1298C) reduce this enzyme's activity in a meaningful share of the population. In people with reduced MTHFR activity, folic acid conversion is less efficient, and some clinicians choose methylfolate instead so the active form is delivered directly. Routine MTHFR genetic testing is not recommended for the general population; it is more often used selectively when a patient has unexplained recurrent pregnancy loss, unexplained clotting events, or a strong family history that a clinician is investigating.

This is a folate-form question, not a folate-Prometrium interaction question. Choosing methylfolate over folic acid does not change how it interacts with Prometrium; the interaction profile described above applies to both forms.

Evidence-status assessment: folate and Prometrium

The interaction that actually matters: anticonvulsants, not folate

Some patients take Prometrium off-label for catamenial epilepsy, where seizures cluster with the menstrual cycle, because progesterone's neuroactive metabolite allopregnanolone affects GABA-A receptor activity. These patients are frequently also on anticonvulsants such as phenytoin, carbamazepine, or valproate. Anticonvulsants are well recognized as folate-depleting drugs, and separately, some of them induce the same liver enzymes that clear Prometrium, which can lower progesterone exposure. That second effect is a Prometrium-anticonvulsant interaction, not a Prometrium-folate interaction, and it is the more clinically important one for this subgroup. A clinician managing this combination typically needs to address anticonvulsant dosing, progesterone dosing, and folate adequacy together rather than treating them as separate decisions.

Valproate deserves specific mention because it is associated with a higher risk of neural tube defects than other anticonvulsants when taken during pregnancy, and the FDA has issued a boxed warning about valproate use in pregnancy for reasons unrelated to migraine prevention. Anyone taking valproate together with Prometrium, particularly during pregnancy or preconception, needs individualized guidance from the prescribing clinician; this is not a question a general folate-and-Prometrium article can safely answer with a specific number.

Folate, homocysteine, and cardiovascular considerations

Reduced MTHFR activity is associated with higher homocysteine levels, and elevated homocysteine has been studied as a cardiovascular and clotting risk marker. Whether lowering homocysteine with folic acid actually reduces cardiovascular events, as opposed to simply lowering a lab value, has been questioned in the broader cardiology literature; specific trial results on this point should be checked against the current primary literature rather than assumed from a summary. Separately, oral estrogen combined with certain progestins carries a documented increase in venous thromboembolism risk, and some observational data suggest that combinations using micronized progesterone rather than synthetic progestins may carry a lower risk, though exact effect sizes vary by study population and route of estrogen delivery and should not be quoted as a single number without checking the specific trial. For a patient with a known MTHFR variant on Prometrium-based HRT, a reasonable and low-risk step is to discuss baseline homocysteine and folate status with the prescriber, not because folate interacts with Prometrium, but because both homocysteine and clotting risk are independently relevant to HRT safety.

Preconception and early pregnancy use

Prometrium is used off-label in reproductive medicine for luteal phase support after IVF and for some cases of threatened miscarriage or recurrent pregnancy loss. Trial evidence on whether progesterone supplementation improves live birth rates has produced mixed results depending on the patient population studied (for example, women with unexplained recurrent loss versus women with early pregnancy bleeding); a reader who wants those specific figures should look at the current systematic reviews directly rather than rely on a number restated secondhand.

Separately from any progesterone effect, folate supplementation before and during early pregnancy is a well-established recommendation from obstetric guideline bodies, generally in the range of 400 to 800 mcg daily for most women planning pregnancy, with a higher dose recommended for women with a prior pregnancy affected by a neural tube defect. Because neural tube closure happens very early, often before a positive pregnancy test, folate supplementation is meant to already be in place, not started once Prometrium begins. There is no evidence that timing folate relative to Prometrium, or the route of Prometrium administration, changes folate's effect.

Practical timing

Prometrium is commonly taken in the evening because it can cause drowsiness, and it absorbs better with food. Folate absorption is not meaningfully food-dependent. Because there is no established interaction, there is no reason to separate the two doses; taking a folate supplement with an evening meal alongside Prometrium is a reasonable and simple routine for most patients. Consistency in timing matters more for Prometrium than for folate, since steady daily dosing helps maintain more even progesterone levels.

Monitoring

Routine folate-specific lab monitoring is not part of standard HRT follow-up for a patient on Prometrium and a typical folate supplement. Two monitoring points are worth raising with a prescriber in specific circumstances:

• Baseline vitamin B12, because folate supplementation can mask the anemia of B12 deficiency while neurological effects of untreated B12 deficiency continue, particularly relevant for patients on high-dose folate.
• Homocysteine and folate status if there is a known MTHFR variant, a personal or family history of unexplained clotting, or concurrent anticonvulsant use.

Unscheduled bleeding on Prometrium should be evaluated per standard HRT practice regardless of folate use; it is not a sign of a folate interaction.

When to seek urgent care

Folate supplementation itself very rarely causes urgent symptoms. However, seek urgent medical attention if you experience symptoms potentially linked to Prometrium or progestin therapy, including sudden leg swelling or pain, chest pain, shortness of breath, sudden severe headache, vision changes, or heavy unscheduled vaginal bleeding, regardless of concurrent supplement use.

What is established, what is plausible, and what is not known

Established: folate and Prometrium do not share a metabolic pathway, and no interaction is flagged in standard references. Plausible but unproven: that folate status could theoretically influence progesterone-responsive gene methylation in the uterus, based on general biology rather than a study in Prometrium users. Not established: that folate changes how well Prometrium works for any of its approved or off-label uses. The genuinely consequential interactions in this space involve anticonvulsants, not folate, and those require individualized clinical management rather than a general answer.